CapitolRadar tracks every publicly disclosed UTHR trade by US congress members and corporate insiders: 6 disclosed trades (2 buys, 4 sells) by 1 tracked traders, from 2022-01-28 to 2023-05-12. Updated daily from official filings.
Want a ping when Congress buys UTHR? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
United Therapeutics Corporation (UTHR) — Healthcare · Biotechnology, market cap about $22.9B.
Cluster watch: 2 distinct tracked traders disclosed buying UTHR in the last 45 days: MAHON PAUL A (officer: EVP & GENERAL COUNSEL), ROTHBLATT MARTINE A (director, officer: Chairperson & CEO).
CapitolRadar analysis
6 disclosures, concentrated in one trader
UTHR’s tracked activity consists of 6 trades by 1 distinct trader between January 28, 2022 and May 12, 2023. The record includes 2 buys and 4 sells, so sells accounted for two-thirds of the disclosed transactions. Because every trade came from a single trader, this is a small and highly concentrated sample rather than a broad signal across multiple filers.
Michael McCaul was the only identified buyer, with 2 purchases. His most recent UTHR buy was reported for March 1, 2022. With no other tracked buyers in the dataset, comparisons of buying behavior across traders are not possible.
4 trades in early 2022, followed by 2 sells in Q2 2023
The activity appeared in two reported quarterly clusters. The first quarter of 2022 contained 4 trades, including both of the tracked buys. The second quarter of 2023 contained 2 trades and no buys, meaning both transactions in that quarter were sells. No additional tracked UTHR trades are included outside those periods within the stated January 2022-to-May 2023 window.
The limited count makes the buy-versus-sell split sensitive to each individual disclosure. It also does not establish a motive for the transactions or indicate how the trader viewed United Therapeutics, a Healthcare company in the Biotechnology industry.
1 buyer also disclosed six other tickers
The UTHR buyer also bought DFAI, NSIT, BAX, MA, WDAY and ALH. Each overlap represents the same single buyer, so these co-purchases show portfolio breadth but do not provide independent confirmation from additional traders.
Congressional transaction reports may be disclosed up to 45 days after a trade, so filing visibility can lag the underlying activity. Reported transaction amounts are generally presented as ranges, making any dollar totals estimates rather than exact figures. Those timing and valuation limits, combined with only 6 trades from 1 trader, constrain the conclusions supported by this record.
Analysis written from the tracked record on 2026-09-11; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2023 Q2 | 2 | 0 | 2 |
| 2022 Q1 | 4 | 2 | 2 |
Who is buying UTHR?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Michael McCaul | 2 | 2022-03-01 | — |
Disclosed trades in UTHR
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2023-05-12 | Michael McCaul | sell | $15,001 - $50,000 | — |
| 2023-05-12 | Michael McCaul | sell | $100,001 - $250,000 | — |
| 2022-03-01 | Michael McCaul | buy | $1,001 - $15,000 | — |
| 2022-03-01 | Michael McCaul | buy | $15,001 - $50,000 | — |
| 2022-01-28 | Michael McCaul | sell | $15,001 - $50,000 | — |
| 2022-01-28 | Michael McCaul | sell | $1,001 - $15,000 | — |
CapitolRadar signal history
NEW PICK 2026-10-14
United Therapeutics Chairperson and CEO Martine Rothblatt was reported as buying about $1.12 million of UTHR stock. The panel passed because the transaction may be misclassified: a news report describes the same 9,500 shares and $117.76 price as an option exercise followed by a sale, while the trade date also requires verification. A confirmed SEC filing showing a true open-market purchase would have materially strengthened the case and could have changed the verdict.
NEW PICK 2026-10-13
United Therapeutics Chairperson and CEO Martine Rothblatt was reported as buying 9,500 UTHR shares for about $1.12 million. The panel passed because the evidence suggests this was an option exercise followed by a sale under a pre-arranged plan, not a clear open-market purchase showing bullish conviction. A filing confirming the shares were bought in the open market and retained—ideally supported by a verified record of successful prior purchases—would have strengthened the case.
NEW PICK 2026-10-01
United Therapeutics EVP and General Counsel Paul A. Mahon was reported as buying about $1.21 million of UTHR shares. The panel passed because the future-dated transaction lacks a filing excerpt, while related coverage describes a sale after an option exercise rather than a clear open-market purchase. A verified SEC filing confirming a discretionary open-market buy, supported by a proven history of similar trades outperforming SPY, could have changed the verdict.
NEW PICK 2026-09-28
United Therapeutics Chairperson and CEO Martine Rothblatt was reported as buying about $1.12 million of UTHR stock. The trade fell short because the underlying Form 4 was not provided, while a related headline describes a 9,500-share sale after an option exercise, raising doubt that this was a true open-market purchase. A verified Form 4 confirming an open-market buy, ideally supported by a proven trading record or additional insider purchases, could have changed the verdict.
NEW PICK 2026-09-16
United Therapeutics Chairperson and CEO Martine Rothblatt reportedly bought about $1.12 million of UTHR stock. The panel passed mainly because the transaction is future-dated and could not be verified as a completed open-market purchase, despite a second insider buyer. An official filing confirming the trade date, price, and purchase details would have provided the evidence needed to reconsider the verdict.
These buyers also bought
Other stocks the tracked buyers of UTHR disclosed buying in the last six months: DELL (1) · NSIT (1) · ASML (1) · MBGL (1) · AJG (1) · KEYS (1).
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in …
Frequently asked questions
Which politicians bought UTHR most?
Michael McCaul leads with 2 disclosed buys.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.